Download PDF
Allgemeine Homöopathische Zeitung 2013; 258(6): 22-25
DOI: 10.1055/s-0033-1357553
Materia
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Homöopathische Prüfsymptome unter Placebo?

Michael Teut
,
Jörn Dahler
Further Information

Publication History

Publication Date:
29 November 2013 (online)

    Permissions and Reprints

Zusammenfassung

Immer wieder wurde in placebokontrollierten homöopathischen Arzneimittelprüfungen beobachtet, dass Prüfsymptome auch bei Probanden unter Placebo auftraten. Was bedeutet dieses Phänomen für die Homöopathie? Hierzu werden mehrere Hypothesen vorgestellt und diskutiert.

Summary

In placebo-controlled homeopathic provings it was repeatedly observed that proving symptoms also occurred in subjects receiving placebo. What does this phenomenon imply for the understanding of homeopathy? Several hypotheses are presented and discussed.

Schlüsselwörter

Arzneimittelprüfung - Placebo - Verumsymptome unter Placebo

Keynodes

Proving - placebo - verum symptoms under placebo
 

  • Literatur

  • 1 Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009; 146: 261-269
    CrossrefGoogle Scholar
  • 2 Bayr G. A model for homeopathic drug tests including statistical analysis. Br Homeopath J 1986; 75: 80-88
    Article in Thieme ConnectGoogle Scholar
  • 3 Boericke W. Homöopathische Mittel und ihre Wirkungen. 9. Aufl. Leer: Grundlagen und Praxis; 2008
    Google Scholar
  • 4 Dantas F et al A systematic review of the quality of homeopathic trials published from 1945 to 1995. Homeopathy 2007; 96: 4-16
    Article in Thieme ConnectGoogle Scholar
  • 5 Dantas F et al Author’s response: we must distunguish symptoms caused by the medicine from other symptoms. Homeopathy 2007; 96: 275-276
    Article in Thieme ConnectGoogle Scholar
  • 6 Hahnemann S. Organon der Heilkunst. Textkritische Ausgabe. Hrsg. J. M. Schmidt Stuttgart: Haug; 1999
    CrossrefGoogle Scholar
  • 7 Häuser W, Bartram C, Bartram-Wunn E, Tölle T. Adverse events attributable to nocebo in randomised controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: a systematic review. Clin J Pain 2012; 28: 437-451
    CrossrefGoogle Scholar
  • 8 Häuser W et al Nocebophänomene in der Medizin: Bedeutung im klinischen Alltag. Dtsch Arztebl Int 2012; 109(26): 459-465
    Google Scholar
  • 9 Kunst M. Okoubaka, ein neues homöopathisches Arzneimittel. AHZ 1972; 3: 116-121
    Article in Thieme ConnectGoogle Scholar
  • 10 Lucae C, Wischner M. Rein oder nicht rein?. ZKH 2010; 54(1): 13-22
    Article in Thieme ConnectGoogle Scholar
  • 11 Möllinger H et al Homeopathic pathogenetic trials produce specific symptoms different from placebo. Forschende Komplementmed 2009; 16: 105-110
    Google Scholar
  • 12 Mora MS, Nestoriuc Y, Rief W. Lessons learned from placebo groups in antidepressant trials. Philos Trans R Soc Lond B Biol Sci 2011; 366: 1879-1888
    Google Scholar
  • 13 Riley DS. Materia Medica of New and Old Homeopathic Medicines. Berlin: Springer; 2012
    CrossrefGoogle Scholar
  • 14 Schlüren E. Okoubaka aubrevillei − ein klinischer Erfahrungsbericht. AHZ 1991; 236: 225-231
    Article in Thieme ConnectGoogle Scholar
  • 15 Sherr J. Dynamics and Methodology of Homeopathic Provings. London: Dynamis School; 1994
    Google Scholar
  • 16 Sherr J, Quirk T. Systematic review of homeopathic pathogenetic trials: an exzess of rigour?. Homeopathy 2007; 96: 273-275
    Article in Thieme ConnectGoogle Scholar
  • 17 Signorini et al Classical and new proving methodology: Provings of plumbum metallicum and piper methysticum and comparison with a classical proving of plumbum metallicum. Homeopathy 2005; 94: 164-174
    Article in Thieme ConnectGoogle Scholar
  • 18 Signorini A. Guest editorial. Finnally some light on the ,Pillar of Homeopathy‘. Homeopathy 2007; 96: 1-2
    Article in Thieme ConnectGoogle Scholar
  • 19 Teut M, Dahler J, Hirschberg U et al Homeopathic drug proving of Okoubaka aubrevillei: a randomised placebo-controlled trial. Trials 2013; 14(1): 96 [open access]
    CrossrefGoogle Scholar
  • 20 Wagner H, Kreutzkamp B, Jurcic K. Inhaltsstoffe und Pharmakologie der Okoubaka aubrevillei-Rinde. Planta Med 1985; 5: 404-407
    Article in Thieme ConnectGoogle Scholar
  • 21 Walach H, Kösters H, Henning T, Haag G. The effects of homeopathic belladonna 30 CH in healthy volunteers − a randomised, double blind experiment. J Psychosom Res 2001; 50: 155-160
    CrossrefGoogle Scholar
  • 22 Walach H. Entanglement model of homeopathy as an example of generalized entanglement predicted by weak quantum theory. Forsch Komplementärmed Klass Naturheilkd 2003; 10: 192-200
    CrossrefGoogle Scholar
  • 23 Walach H, Sherr J, Schneider R et al Homeopathic proving symptoms: result of a local, non-local, or placebo-process? A blinded, placebo-controlled pilot study. Homeopathy 2004; 93: 179-185
    Article in Thieme ConnectGoogle Scholar
  • 24 Walach H. Generalized entanglement: a new theoretical model for understanding the effects of complementary and alternative medicine. J Altern Complement Med 2005; 11(3): 549-559
    CrossrefGoogle Scholar
  • 25 Walach H. Homeopathic pathogenetic trials produce more specific than non- specific symptoms: results from two double-blind placebo controlled trials. J Psychopharm 2008; 22(5): 543-552
    CrossrefGoogle Scholar
  • 26 Walach H. Homeopathic pathogenetic trials: A summary of 20 years of reflection, data collection, and analysis. In: Witt C, Albrecht H, eds New Directions in Homeopathy Research. Essen: KVC; 2009
    Google Scholar